Clinical Trials Logo
  1. Home
  2. Metastatic Renal Cell Cancer
  3. NCT02555748

Therapeutic Drug Monitoring of Sunitinib and Pazopanib in Advanced or Metastatic Renal Cell Carcinoma — SUP-R  

Metastatic Renal Cell Cancer Clinical Trial

Official title:
Therapeutic Drug Monitoring of Sunitinib and Pazopanib in Advanced or Metastatic Renal Cell Carcinoma

Clinical Trial Summary

This pilot study is an open-label interventional study, prospective, non-comparative, sequential (two stages), national, multicenter study. Patients starting therapy with sunitinib or pazopanib as standard first line treatment for advanced or metastatic renal cell carcinoma will enter the study in one of the two cohorts (115 patients will be treated by sunitinib and 99 patients will be treated by pazopanib). The purpose of this study is to examine the feasibility of sunitinib and pazopanib dose individualisation based on therapeutic drug monitoring (TDM) and to assess the benefit of this approach in terms of tolerance and efficacy compared with the current empirical method based only on tolerance observation.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02555748
Study type Interventional
Source Institut Claudius Regaud
Contact
Status Completed
Phase Phase 4
Start date November 17, 2015
Completion date January 16, 2020
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT02664883 - Myeloid Derived Suppressor Cells Clinical Assay in Finding Kidney Cancer
Completed NCT03229278 - Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma Phase 1
Completed NCT01462214 - Study of Everolimus and Low-dose Cyclophosphamide in Patients With Metastatic Renal Cell Cancer Phase 1/Phase 2
Completed NCT02899078 - Ibrutinib and Nivolumab in Treating Patients With Previously-Treated Metastatic Kidney Cancer Phase 1/Phase 2
Terminated NCT00670748 - Chemotherapy Followed by ESO-1 Lymphocytes and Aldesleukin to Treat Metastatic Cancer Phase 2
Completed NCT01829841 - A Study of Famitinib in Patients With Advanced Metastatic Renal Cell Cancer Phase 2
Active, not recruiting NCT01767636 - Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Phase 2
Recruiting NCT02542202 - Stereotactic Body Radiation Therapy in Treating Patients With Metastatic or Recurrent Kidney Cancer N/A
Completed NCT02626130 - Tremelimumab With or Without Cryoablation in Treating Patients With Metastatic Kidney Cancer Early Phase 1
Completed NCT01522820 - Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors Phase 1
Active, not recruiting NCT01590069 - Aerosolized Aldesleukin in Treating Patients With Lung Metastases Phase 1
Recruiting NCT01884961 - Radiotherapy as an Immunological Booster in Patients With Metastatic Melanoma or Renal Cell Carcinoma Treated With High-dose Interleukin-2 Phase 2
Completed NCT02599194 - 18F-FSPG PET/CT for Cancer Patients on Therapy Phase 2
Completed NCT01246843 - Evaluation of Cognitive Function of Patients With Sunitinib or Sorafenib N/A
Completed NCT01258348 - A Phase 1b Trial in Patients With Renal Cell Cancer Phase 1
Completed NCT00428220 - A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study. N/A
Active, not recruiting NCT03092856 - Axitinib With or Without Anti-OX40 Antibody PF-04518600 in Treating Patients With Metastatic Kidney Cancer Phase 2
Completed NCT02843607 - Combination of Cryosurgery and NK Immunotherapy for Advanced Kidney Cancer Phase 1/Phase 2
Completed NCT02318771 - Radiation Therapy and MK-3475 for Patients With Recurrent/Metastatic Head and Neck Cancer, Renal Cell Cancer, Melanoma, and Lung Cancer Phase 1
Active, not recruiting NCT02689167 - Study to Assess Various Sunitinib Schedules in Renal Cell Carcinoma Phase 2